Shell Asset Management CO Fibrogen Inc Transaction History

Shell Asset Management CO

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 10, 2021	SELL	$31.0 - $55.72 $220,627 - $396,559	-7,117 Closed	0 $0
Q2 2020 Aug 10, 2020	SELL	$32.57 - $42.83 $2,247 - $2,955	-69 Reduced 0.96%	7,117 $288,000
Q1 2020 May 11, 2020	SELL	$23.3 - $45.96 $2,563 - $5,055	-110 Reduced 1.51%	7,186 $250,000
Q4 2019 Feb 13, 2020	SELL	$34.58 - $48.06 $5,256 - $7,305	-152 Reduced 2.04%	7,296 $313,000
Q3 2019 Nov 12, 2019	SELL	$36.98 - $48.45 $2,366 - $3,100	-64 Reduced 0.85%	7,448 $275,000
Q2 2019 Aug 12, 2019	SELL	$35.13 - $55.53 $6,042 - $9,551	-172 Reduced 2.24%	7,512 $339,000
Q4 2018 Feb 13, 2019	SELL	$37.97 - $60.16 $26,579 - $42,112	-700 Reduced 8.35%	7,684 $356,000
Q2 2018 Aug 10, 2018	SELL	$44.9 - $64.95 $20,115 - $29,097	-448 Reduced 5.07%	8,384 $525,000
Q4 2017 Feb 09, 2018	BUY	$41.95 - $60.1 $370,502 - $530,803	8,832	8,832 $419,000

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Shell Asset Management CO, based on Form 13F filings with the SEC.

Stay updated on Shell Asset Management CO with notifications on news.